CV Satu Mustjoki

1

CURRICULUM VITAE

1. Full name • Mustjoki, Satu Maarit • Female • Date of CV 29th September 2017

2. Date and place of birth, nationality, current residence • January 8th 1972, Lahti, Finland • Finnish • Contact information:

Hematology Research Unit Helsinki Biomedicum Helsinki University of Helsinki Haartmaninkatu 8, 00290 Helsinki, Finland satu.mustjoki@helsinki.fi www.helsinki.fi/hematology +358-9-471-71898 (tel), +358-9-471-71897 (fax)

3. Education and degrees awarded • Adjunct professor (docent), Experimental hematology, University of Helsinki, Finland, 20.04.2011 • Doctor of Medical Sciences (PhD, Thesis accepted with distinction, Title: Urokinase, Urokinase Receptor, and

ICAMs in Human Leukemia), University of Helsinki, Finland, 27.02.2001 • Licenciate in Medicine (MD), University of Helsinki, Finland, 30.09.1997

4. Other training, qualifications and skills • Specialist in Clinical Chemistry (Laboratory hematology), University of Helsinki, Finland, 28.08.2008 • GCP (good clinical practice) courses related to clinical drug studies

5. Current position • Professor in Translational hematology, University of Helsinki, Helsinki, Finland, 1.9.2017- (full professor, 50%

leave until 31.12.2017 due to Finnish Cancer Institute professorship) • Research professor for the Finnish Cancer Institute, 1.1.2015-(31.12.2017) • Specialist doctor (5% position), Comprehensive Cancer Center, Helsinki University Central Hospital (HUCH),

Helsinki, Finland, 1.7.2012-

6. Previous work experience and career breaks • Deputy professor in Clinical Chemistry and Hematology (35% position), University of Helsinki, Finland, 1.3.2015-

31.8.2017 • Senior Academy Research Fellow, Hematology Research Unit Helsinki, Helsinki, Finland 1.8.2010-31.12.2014 • Academy Clinical Researcher, Hematology Research Unit Helsinki, HUCH, Helsinki, Finland, 1.10.2008-31.7.2010 • Research doctor, Department of Medicine, Division of Hematology, HUCH, Helsinki, Finland, 1.5.2007-31.07.2007 • Resident in clinical hematology, Division of Hematology, HUCH, Helsinki, Finland, 1.3.-30.4 and 1.9-27.9.07 • Doctor assistant and clinical lecturer, Dept of Clinical Chemistry, UH, Finland 1.8.2006-31.1.2007 • Resident in Clinical Chemistry, Laboratory of Hematology, HUCH, Helsinki, Finland, 1.10.2001-31.03.2002,

1.4.2003-31.7.2006 and 1.2-28.02.2007 • Post-Doctoral researcher, Molecular Cancer Biology Program (Group prof. K. Alitalo), UH, Finland, 1.12.2000-

30.09.2001 • PhD student, Dept of Virology (Group prof. A. Vaheri), UH, Finland, 1.10.1997-30.11.2000 • Career leaves: Maternity leaves 1.4.2002-30.3.2003 and 1.12.2004-30.11.2005

7. Most important scientific and academic administrative positions • Head of the department of Clinical Chemistry and Hematology, University of Helsinki, 1.3.2015-

CV Satu Mustjoki

2

• Vice director of the Doctoral Program in Clinical research (Doctoral School of Health Sciences, University of Helsinki), 1.1.2014-31.12.2017

• Board member of the Nordic CML study group, 1.1.2010-

8. Most important scientific acknowledgements and awards, memberships in science academies • Nomination for the Helsinki Institute of Life Science (HiLife) Fellow group for years 2017-2020 • ERC Consolidator grant awardee 2015 • Instrumentarium Science foundation fellow award (100 000 eur) 2014 • Senior research fellowship of the Academy of Finland 2010-2015 • Clinical researcher fellowship from the Academy of Finland 2008-2010 • Nomination for the Biocentrum Helsinki research group for years 2014-2016 • One of the 7 research groups of the P-MOLMED (personalized molecular medicine) consortium which was ranked

the number 1 research network in the University of Helsinki evaluation in 2012 in the category of society impact • PhD thesis 2001 (Urokinase, Urokinase Receptor, and ICAMs in Human Leukemia) accepted with distinction • Several abstract awards (2008 XXII Olomouc Hematology Days, Olomouc, Czech Republic; 2008 13th Congress of

the European Hematology Association, Copenhagen, Denmark; 2009, 14th Congress of the European Hematology Association, Berlin, Germany; 2011, 16th Congress of the European Hematology Association, London, UK; 2012, 54th annual meeting of the American Society of Hematology, Outstanding Abstract Achievement Award, Atlanta, USA)

• Memberships in professional societies: o Finnish Medical Association, 1993- o Finnish Society of Hematology, 2002- o The American Society of Hematology, 2008- o The European Society of Hematology, 2008-

9. Most important research funding • European Research Council (ERC) consolidator grant 2015-2020, 2 047 000€ • Academy of Finland 2015-2018, 458 215€ • Finnish Cancer Organizations major grant 2017-2019, 450 000€ • Sigrid Juselius Foundation 2017-2020, 75 000€/year • HiLife Fellow 2017-2020, 180 000€ • State funding for university level health research 2014-2017, 297 500€ • Instrumentarium Science Foundation 2014-2015, 100 000€ • Sigrid Juselius Foundation 2014-2016, 150 000€ • Finnish Cancer Organizations, 2015-2016, 100 000€ • Pfizer biomarker program, 2014-2017, 425 000€ • Nordic Cancer Union, 2013-2015, 240 000€ • Finnish Cancer Organizations, 2013-2014, 100 000€ • Biocentrum Helsinki 2014-2016, 135 000€ • Academy of Finland, 2013-2015, 284 168€ • Sigrid Juselius Foundation 2010-2013, 144 000€ • Academy of Finland (Academy Research fellow) 2010-2015, 391 510€ • Total competitive research funding as a PI during 2008-2016: 5 907 000€ and funding for academic biomarker

trials during 2009-2016: 1 223 000€

10. Research leaderships and supervised doctoral dissertations (as supervisor appointed by a university) • PhD thesis supervision (finished):

o M.Sc. Sari Jalkanen (Hernesniemi), University of Helsinki, Finland, 2007-2012 o M.Sc. Anna Kreutzman, 2008-2012 (thesis with honor) o MD Hanna Rajala (née Koskela), 2010-2014 (thesis accepted with honorary grade) o M.Sc. Mette Ilander, 2011-2016 o M.Sc. Emma Andersson, 2012-2017 o M.Sc. Paavo Pietarinen, 2013-2017 o MD Mohammed ElMissiry, 2013-2017

CV Satu Mustjoki

3

o MD Stina Söderlund, University of Uppsala, Sweden, 2013-2017

• PhD thesis supervision (ongoing): o M.Sc. Heikki Kuusanmäki, 2012- o Med. Student Paula Savola, 2013- o Med. Student Olli Dufva, 2014- o MD Oscar Bruck, 2015- o MD Shady Awad, 2015- o Med. Student Sofie Lundgren, 2015 – o MD Helena Hohtari, 2016- o M.Sc. Daehong Kim, 2016- o M.Sc. Henna Hakanen, 2017- o M.Sc. Moon Hee Lee, 2017- o Med. Student Jani Huuhtanen, 2017- o M.Sc. Dipabarna Bhattacharya, 2017-

• Master’s thesis and MD thesis supervision (finished): o Mette Ilander, 2011 o Emma Andersson 2012 o Kati Penttinen 2012 o Emmi Vakkila 2016 o Sabrina Bortoluzzi 2015 (University of Padua, Italy) o Jaakko Eskelinen 2016 o Vanessa Gasparini 2016 (University of Padua, Italy) o Moon Lee Hee 2017

• Supervision of post-doc researcher (main supervisor): o PhD Can Hekim 1.4.2012-31.7.2014 o PhD Tiina Kelkka 1.4.2013- o PhD Giljun Park 1.1.2015- o PhD Anna Kreutzman 1.6.2015- o MD, PhD Mikko Keränen 1.8.2015- o MD, PhD Hanna Rajala 1.1.2017- o PhD Bhagwan Yadav 1.2.2017-

12. Other scientific expert positions and scientific achievements • Member of the American Society of Hematology (ASH) scientific committee (myeloid neoplasia) 2016- • Board member of Helsinki Life Science steering group, 2016-2016 • Board member of the Finnish Society of Hematology, 2006-2010 • Member of the Editorial board: International Trends in Immunity 2013-, Cytokine 2014- • Referee in international journals (such as Blood, Leukemia, Haematologica, Blood Cancer Journal, Future

Oncology, Cancer, Oncotarget, Cytokine, BioDrugs, Critical Reviews in Oncology/Hematology, Tumor Biology) in topics related to hematology and immunology, 2001-

• Pre-examiner of a Doctoral dissertation 3 times (University of Oulu 2014, University of Helsinki 2015, University of Oulu 2016)

• Abstract reviewer for the 16th, 18th and 21st Congress of the European Hematology Association, 2011, 2013, 2016 • Abstract reviewer for the 54th Congress of the American Society of Hematology, 2014 • External international expert in EU funded project: Innovation of Microscope Morphology Education in Hematology

Using Internet Virtual Interactive Method (CZ.1.07/2.2.00/07.0294), 2008-2010 • Principal investigator or study steering group member in international clinical studies: 3 international, multicenter

academic studies run in European countries (http://clinicaltrial.gov NCT01725204, NCT00852566 and NCT01596114) 2009-

• Principal investigator in 6 international biomarker discovery programs in association with clinical drug studies run in European countries 2009-

• Sub-investigator in 24 international, multicenter clinical studies in hematological malignancies using novel targeted drugs 2007-

CV Satu Mustjoki

4

• Assessment of professorship positions: o Sweden 2017 o USA 2016

• International peer evaluation of funding applications: o Estonia 2012, Austria 2013, United Kingdom 2014, Czech Republic 2015, UK 2016, ERC 2016&2017,

Poland 2017, France 2017, UK 2017, Austria 2017 • Thesis committee member for several PhD students (currently group member in 7 PhD thesis committees) 2010- • Important international invitation lectures

o Only the invited lectures in 2016-2017 are listed. Similar invited lectures regularly during previous years o Immuno-Oncology Conference, Lisbon, Portugal, 2017 o European LeukemiaNet conference, Mannheim, Germany, 2017 o CML Scientific seminar, Sapporo, Okinawa and Tokyo, Japan, 2017 o European Hematology Association Conference, Copenhagen, Denmark, 2016 o Highlights of past EHA conference, Dubai, United Arab Emirates, 2016 o LinKou Chang Gung Memorial Hospital, Taipei, Taiwan, 2016 o Control-T International Conference of Mature T-cell lymphomas, Frankfurt, Germany, 2016 o CML Scientific seminar, Osaka and Tokyo, Japan, 2016 o European Investigators in CML seminar, Versailles, France, 2016 o NCMLSG conference, Malmö, Sweden, 2016

13. Merits in teaching and pedagogical competence • Board member in the Doctoral programme in clinical research (University of Helsinki) 2013- • Professor in Clinical Chemistry and Hematology responsible for basic and specialist training in the University of

Helsinki, Finland, 1.3.2016- • Lecturer in courses associated to Helsinki Biomedical Graduate school and to Specialist training in Internal

Medicine and Clinical Chemistry 2010- • Lecturer in CML school organized by CML study group 2010-2013 • Doctor assistant and clinical lecturer, Department of Clinical Chemistry, University of Helsinki, Finland 1.8.2006-

31.1.2007 • Thesis committee member for several PhD students (currently group member in 6 PhD thesis committees) 2010-

14. Scientific and societal impact of research Altogether, 100 publications which consist of 86 original research journal articles, 12 review articles, 1 chapter in research books and 1 conference proceedings article all of which are published in peer-reviewed scientific journals. They have been cited 2448 times (without self-citations), h-index 24. 65 of the publications are from the last 5 years. First author in 15 publications, and the last corresponding author in 41 publications. 37 original research articles with IF>10. The mean impact factor of all original research publications is 9.0. Link to the full publication list: http://www.ncbi.nlm.nih.gov/pubmed/?term=mustjoki

CV Satu Mustjoki

5

PUBLICATION LIST

• List of the most important publications during the last 10 years and their citations Articles related to LGL lymphoproliferation, JAK-STAT pathway, RA, and genetics:

1. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Jr., Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13. (Groundbreaking observation demonstrating that LGL leukemia is caused by activating STAT3 mutations. Corresponding author. Appeared also in Nature Genetics research highlights and recommended by F1000 Prime.) IF 59.588, JR 1/151 Medicine, General&Internal, cited 239 times

2. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, Andersson EI, Jerez A, Clemente

MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP, Jr., Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541-4550). (This was the first time to discover somatic mutations in STAT5 gene. The mutation type also correlated with clinical disease phenotype. The article was highlighted in Hematologist and "This week in Blood" series. Senior, corresponding author.) IF 11.841, JR 2/70 Hematology, Cited 77 times

3. Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., McDonald, T.J.,

Rajala, H., Ramelius, A., Barton, J., Heiskanen, K., Heiskanen-Kosma, T., Kajosaari, M., Murphy, N.P., Milenkovic, T., Seppanen, M., Lernmark, A., Mustjoki, S., Otonkoski, T., Kere, J., Morgan, N.G., Ellard, S. & Hattersley, A.T. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Gen 2014;46:812-814. (Discovery of novel germline STAT3 mutations in patients with multi-organ autoimmune disease) IF 31.616, JR 2/165 Genetics&heredity, cited 89 times

4. Rajala, H.L., Olson, T., Clemente, M.J., Lagstrom, S., Ellonen, P., Lundan, T., Hamm, D.E., Zaman, S.A., Lopez

Marti, J.M., Andersson, E.I., Jerez, A., Porkka, K., Maciejewski, J.P., Loughran, T.P. & Mustjoki, S. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 2015;100:91-99. (Discovery of multiple STAT3 mutations in expanded CD8+ T cells and their association with rheumatoid arthritis) IF 6.671, JR 4/70 Hematology, cited 13 times

5. Andersson E, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T,

Clemente MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, Maciejewski JP, Mustjoki S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL Leukemia. Leukemia 2016;30:1204-1208. (Discovery of novel STAT3 mutations in LGL leukemia) IF 12.104, JR 1/70 Hematology, cited 2 times

6. Andersson E, Tanahashi T, Sekiguchi N, Gasparini V, Bortoluzzi S, Matsuda K, Mitsui T, Eldfors S, Bortoluzzi S,

Coppe A, Binatti A, Lagsrtom S, Ellonen P, Fukushima N, Nishina S, Senoo N, Sakai H, Nakazawa H, Kwong Y-L, Loughran TP, Maciejewski JP, Mustjoki S*, Ishida F*. *equal senior authors. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood 2016 Nov 17;128(20):2465-2468. (Association of STAT5B mutations to CD4+ phenotype of LGL leukemia)

IF 11.841, JR 2/70 Hematology 7. Savola P*, Kelkka T*, Rajala H, Kuuliala A, Kuuliala K, Eldfors S, Ellonen P, Lagstrom S, Lepisto M, Hannunen T,

Andersson EI, Khajuria RK, Jaatinen T, Koivuniemi R, Repo H, Saarela J, Porkka K**, Leirisalo-Repo M,**, Mustjoki S**. *,**Equal contribution. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 2017;8:15869. (Seminal discovery of clonal expansions carrying somatic mutations in patients with newly diagnosed rheumatoid arthritis)

CV Satu Mustjoki

6

IF 12.124, JR 3/64 Multidisciplinary Sciences Articles related to clonal lymphocyte expansions and tumor immunology: 8. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Hoglund M,

Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405. (Discovery of clonal LGL expansion as an off-target effect of targeted leukemia therapy and its association with autoimmune disorders) IF 12.104, JR 1/70 Hematology, cited 159 times

9. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal

T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82. (Discovery of clonal T- and NK-cells in untreated leukemia patients. Senior, corresponding author responsible for the whole study. Editorial was written related to this article) IF 11.841, JR 2/70 Hematology, cited 67 times

10. Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; Apr;27(4):914-24. (Discovery of lymphocyte mobilization induced by dasatinib therapy, putative novel mode of lymphocyte activation).

IF 12.104, JR 1/70 Hematology, cited 20 times. 11. Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z,

Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor (TKI) therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). J Clin Oncol. 2017;35(2):175-184. (Characterization of immunological changes during targeted kinase inhibitor therapy and their correlation with therapy response. Pan-European collaboration in clinical trial. I was in the immunology substudy steering board and responsible for the trial design together with Dr. Wolf) IF 20.982, JR 5/213 Oncology, cited 2 times.

12. Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A,

Kovanen PE, Porkka K, Lee FY, Mustjoki S. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunol Res. 2017 Feb;5(2):157-169. (Discovery of beneficial immunomodulatory effects of dasatinib in murine solid tumor models).

13. Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H, Kasanen T, Koskenvesa P,

Soderlund S, Hoglund M, Markevarn B, Sjalander A, Lotfi K, Dreimane A, Lubking A, Holm E, Bjoreman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108-1116. (Discovery of immunological biomarker for successful therapy discontinuation in leukemia patients. Pan-European collaboration in clinical trial. PI of the study) IF 12.104, JR 1/70 Hematology, cited 2 times.

Articles related to novel therapies: 14. Andersson EI, Putzer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oles M, Zhang H,

Adnan S, Lagstrom S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brummendorf TH, Kytola S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2017. IF 12.104, JR 1/70 Hematology

Tiedostonimi: Mustjoki_CV_v1.docx Kansio: /Users/satu/Library/Containers/com.microsoft.Word/Data/Documents Malli: /Users/satu/Library/Group Containers/UBF8T346G9.Office/User

Content.localized/Templates.localized/Normal.dotm Otsikko: CURRICULUM VITAE Aihe: Tekijä: Satu M. Avainsanat: Kommentit: Luontipäivä: 29.9.2017 19.30.00 Version numero: 3 Viimeksi tallennettu: 29.9.2017 19.54.00 Viimeksi tallentanut: Mustjoki, Satu M Kokonaismuokkausaika: 13 minuuttia Viimeksi tulostettu: 29.9.2017 19.55.00 Viimeisestä täydestä tulostuksesta Sivuja: 6 Sanoja: 2 732 Merkkejä: 16 843 (noin)